Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002)

ConclusionsAdding docetaxel to CS in preoperative chemotherapy for extensive nodal metastasis improved neither short-term outcomes nor long-term survival. Preoperative chemotherapy with CS followed by D2  + PAN dissection and postoperative S-1 remains the standard of care for patients with extensive nodal metastasis.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research

Related Links:

Purpose of review The aim of this study was to review studies published within the past year regarding management of gastric cancer. Recent findings Laparoscopic gastrectomy achieves equivalent survival compared with open gastrectomy in early stage and locally advanced gastric cancer. Adjuvant chemotherapy with 6 months of S-1 and oxaliplatin was superior to 12 months of S-1, and the addition of postoperative radiation therapy did not improve survival. The FLOT regimen is the new standard for preoperative chemotherapy. In metastatic gastric cancer, the addition of docetaxel to S-1 and cisplatin failed to improve overa...
Source: Current Opinion in Gastroenterology - Category: Gastroenterology Tags: STOMACH AND DUODENUM: Edited by Mitchell L. Schubert Source Type: research
Laparoscopy-assisted distal gastrectomy offered better short-term, post-surgical outcomes for patients with locally advanced gastric cancer who were undergoing neoadjuvant chemotherapy.  
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
In patients with locally advanced gastric cancer, laparoscopy-assisted distal gastrectomy (LADG) after neoadjuvant chemotherapy appears to offer more short-term benefits than does open gastrectomy, according to Chinese researchers.Reuters Health Information
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
ConclusionsAmong stage IB/IIA gastric cancer patients that underwent gastrectomy with curative-intent, post-operative adjuvant chemotherapy may be considered for patients carrying the TP53 codon 72 Pro/Pro polymorphism.Clinical trial identificationNCT01905969.Editorial acknowledgementChristopher Brooks of Bioscience Editing Solutions.Legal entity responsible for the studyThe authors.FundingMinistry of Education, Culture, Sports, Science and Technology, Japan.DisclosureY. Ohmori: Full / Part-time employment: Astellas Pharma Inc.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
This randomized clinical trial examines the safety and advantages of laparoscopy-assisted distal gastrectomy over the traditional open gastrectomy and following chemotherapy for adults with gastric adenocarcinoma.
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
In this study, an open-label, single cente r, phase 2 randomized clinical trial with a noninferiority design, the authors assessed outcomes at 3 years. All patients received neoadjuvant therapy of oxaliplatin and capecitabine before their operation. Li and colleagues reported significantly lower postoperative complication rates, less postope rative pain, and better adherence to and completion of adjuvant therapy among trial participants.
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
This study aimed to identify the risk factors for NAFLD after gastrectomy for gastric cancer.MethodsA total of 721 patients who underwent gastrectomy for gastric cancer and plane abdominal computed tomography (CT) preoperatively and 1 year after surgery were included in this study. NAFLD was defined as having a mean hepatic CT attenuation value of  
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
Publication date: Available online 20 September 2019Source: Cirugía Española (English Edition)Author(s): Vicente Munitiz, Angeles Ortiz, David Ruiz de Angulo, Luisa F. Martinez de Haro, Pascual ParrillaAbstractThere is significant controversy in the management of cardiac cancer. It seems unanimous that Siewert type I tumors be operated on as cancer of the esophagus and Siewert type III as gastric cancer. However, for “true” cancer of the gastric cardia or Siewert II, the authors do not agree. There is the obvious need for free proximal and distal margins, as well as correct lymphadenectomy. For so...
Source: Cirugia Espanola - Category: Surgery Source Type: research
AbstractBackgroundWhether or not surgery alone is sufficient for treating patients with pathological stage T1N2M0 (Stage IIA), T1N3a/bM0 (Stage IIB/IIIB), and T3N0M0 (Stage IIA) gastric cancer who were not indicated for adjuvant treatment according to the Japanese gastric cancer treatment guideline remains unclear.MethodsWe retrospectively reviewed the clinical records of 236 patients who had been diagnosed with pT1N2-3b/pT3N0 gastric cancer and undergone R0 gastrectomy with lymph node dissection between January 2000 and December 2012 at the National Cancer Center Hospital, Japan.ResultsThe 5-year recurrence-free survival ...
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
ConclusionsOur multicenter dataset analysis indicated that the prognosis of patients with gastric cancer migration from clinical stage I to pathological stage II or III was independent of the surgical approach.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Taxotere